A high‐performance liquid chromatography–tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple‐dose pharmacokinetic study

Imigliptin is a novel DPP‐4 inhibitor, designed to treat type 2 diabetes mellitus (T2DM). A selective and sensitive method was developed using high performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) to simultaneously quantify imigliptin, its five metabolites, and al...

Full description

Saved in:
Bibliographic Details
Published in:Biomedical chromatography 2018-11, Vol.32 (11), p.e4324-n/a
Main Authors: Liu, Yang, Song, Ling, Yao, Xueting, Wu, Yiwen, Liu, Hongzhong, Zhao, Qian, Jiang, Ji, Shi, Chongtie, Ma, Xifeng, Zhou, Huimin, Liu, Dongyang, Hu, Pei
Format: Article
Language:English
Subjects:
Alogliptin
Chromatography, High Pressure Liquid - methods
Diabetes Mellitus, Type 2 - drug therapy
Human plasma and urine
Humans
Hypoglycemic Agents - blood
Hypoglycemic Agents - pharmacokinetics
Hypoglycemic Agents - therapeutic use
Hypoglycemic Agents - urine
Imidazoles - blood
Imidazoles - pharmacokinetics
Imidazoles - therapeutic use
Imidazoles - urine
Imigliptin and its metabolites
LC–MS/MS
Limit of Detection
Linear Models
Pharmacokinetics
Piperidines - blood
Piperidines - pharmacokinetics
Piperidines - therapeutic use
Piperidines - urine
Pyridines - blood
Pyridines - pharmacokinetics
Pyridines - therapeutic use
Pyridines - urine
Reproducibility of Results
T2DM
Tandem Mass Spectrometry - methods
Uracil - analogs & derivatives
Uracil - blood
Uracil - pharmacokinetics
Uracil - therapeutic use
Uracil - urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!